How Much Does Zepbound Cost in Oregon in 2026?

Zepbound List Price and Cash-Pay Cost in Oregon

The retail price for Zepbound at Oregon pharmacies is $1,059 per month regardless of dose strength. Eli Lilly uses a flat pricing structure across the 2.5 mg through 15 mg single-dose pen options 1. This price applies at Walgreens, CVS, Fred Meyer, Safeway, and Costco pharmacy locations throughout Portland, Eugene, Salem, Bend, and other Oregon cities.

Cash-pay patients face the full $1,059 monthly cost without intervention. Some pharmacy discount aggregators show minimal variation between Oregon locations, typically within $20 of the list price. The Costco member prescription program and certain independent pharmacies may offer slightly lower cash prices, though savings rarely exceed 5% off list 2.

Compared with semaglutide 2.4 mg (Wegovy), which lists at approximately $1,349 per month, Zepbound's list price sits roughly $290 lower. Both drugs received FDA approval for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity 1.

Oregon Medicaid Coverage for Zepbound

Oregon Health Plan (Medicaid) covers Zepbound with prior authorization for chronic weight management. The Oregon Health Authority's Pharmacy and Therapeutics Committee added tirzepatide to the preferred drug list in 2024 following review of the SURMOUNT trial program 3.

Prior authorization requirements for Oregon Medicaid typically include documentation of BMI ≥30 (or ≥27 with comorbidity), a minimum 3-month trial of lifestyle modification, and prescriber attestation that the patient has no contraindicated conditions such as personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 4.

Approval periods run 6 to 12 months with renewal contingent on documented weight loss of at least 5% from baseline. The Oregon Health Authority references Endocrine Society guidelines recommending pharmacotherapy as adjunct to behavioral intervention for patients meeting BMI criteria 5. Denial rates for initial PA requests in Oregon run approximately 15-20%, most commonly due to incomplete documentation rather than medical ineligibility.

Commercial Insurance Coverage in Oregon

Major commercial insurers in Oregon have added Zepbound to formularies with varying tier placements and PA requirements. Providence Health Plan, Regence BlueCross BlueShield, Moda Health, and PacificSource cover Zepbound on specialty or non-preferred brand tiers 6.

Typical cost-sharing for Oregon enrollees breaks down by plan design. High-deductible plans require full cost until deductible is met. Preferred brand tier copays range from $50 to $150 per fill. Specialty tier coinsurance averages 25-30%, placing patient responsibility at $250-$320 per month before manufacturer assistance 7.

Self-insured employer plans (covering roughly 60% of commercially insured Oregonians) make independent formulary decisions. Large Oregon employers including Nike, Intel, and OHSU have reportedly added GLP-1 receptor agonist coverage for weight management following data showing reduced cardiovascular events 8. The American Heart Association's 2024 statement on obesity pharmacotherapy supports coverage of FDA-approved anti-obesity medications for eligible patients 8.

Kaiser Permanente Northwest, serving over 600,000 Oregon members, covers tirzepatide with step therapy requiring prior trial of lower-cost options. Patients must demonstrate inadequate response to or intolerance of at least one formulary alternative before Zepbound approval 9.

The Eli Lilly Savings Card Program

Eli Lilly's Zepbound Savings Card reduces out-of-pocket cost to $25 per month for commercially insured patients whose plans cover the medication. The card covers up to $563 per fill, bridging the gap between insurance payment and the $25 patient cost 1.

Eligibility requires commercial insurance with Zepbound on formulary. Patients on government insurance (Medicare, Medicaid, Tricare, VA) cannot use the savings card per federal anti-kickback statute restrictions 10. The program has no income requirement for eligible patients.

For uninsured or cash-pay patients, Lilly introduced the LillyDirect program offering Zepbound vials (not pens) at $399 for a one-month supply at the 2.5 mg and 5 mg doses, and $549 for higher doses. Oregon patients can access LillyDirect through participating telehealth providers operating in the state 11.

Oregon residents without commercial coverage should calculate total annual cost: the savings card at $25/month yields $300 annually, versus $12,708 at list price. That represents a 97.6% reduction in patient cost when the card applies.

Compounded Tirzepatide in Oregon: Legality and Pricing

Compounded tirzepatide from licensed 503A pharmacies is legal in Oregon as of May 2026. The FDA's initial shortage designation for tirzepatide allowed 503A compounders to produce the drug; although the shortage status has faced ongoing regulatory review, Oregon Board of Pharmacy regulations permit state-licensed compounding pharmacies to fill patient-specific prescriptions for tirzepatide when compliant with state and federal requirements 12.

Average cost for compounded tirzepatide in Oregon runs $249 per month, roughly 76% below Zepbound's list price. Pricing varies by pharmacy and dose, ranging from $150 for lower doses (2.5-5 mg weekly) to $350 for higher doses (12.5-15 mg weekly) 13.

Oregon-based 503A compounding pharmacies must hold valid Oregon Board of Pharmacy licensure and comply with USP 797 sterile compounding standards. Patients should verify their pharmacy's sterile compounding accreditation before filling prescriptions 14.

Key distinctions from brand Zepbound: compounded formulations use tirzepatide base (sourced from FDA-registered bulk chemical suppliers), may differ in excipients, and lack the proprietary KwikPen delivery device. Patients inject using standard insulin syringes. The SURMOUNT-1 trial enrolled 2,539 participants using the manufactured product specifically, so efficacy data applies directly only to brand Zepbound 3.

Telehealth Access to Zepbound in Oregon

Oregon law permits full prescriptive authority via telehealth for scheduled medications including Zepbound. Oregon House Bill 2508 (2021) made permanent the telehealth prescribing flexibilities introduced during COVID-19, allowing initial and ongoing prescriptions without in-person visits 15.

Multiple telehealth platforms serve Oregon patients seeking Zepbound prescriptions. Costs for telehealth consultations typically run $50-$150 for initial evaluation, with monthly follow-up visits ranging from $30-$75. Some platforms bundle consultation fees into medication pricing 16.

Prescribers must hold an active Oregon medical license or practice under the Interstate Medical Licensure Compact, of which Oregon is a member state. The Oregon Medical Board requires that telehealth prescribers establish a bona fide patient-provider relationship before writing controlled or specialty prescriptions 17.

Dr. Robert Kushner, professor of medicine at Northwestern University, has noted: "Telehealth has become a legitimate primary access point for obesity pharmacotherapy, particularly in states like Oregon where rural populations face significant geographic barriers to specialist care" 17.

Clinical Efficacy: What Oregon Patients Can Expect

SURMOUNT-1 (N=2,539) demonstrated tirzepatide's dose-dependent weight loss in adults with obesity or overweight with comorbidities. At 72 weeks, mean body weight reduction reached 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) versus 3.1% for placebo 3. The proportion achieving ≥5% weight loss was 85-91% across tirzepatide doses versus 35% for placebo.

SURMOUNT-2 studied tirzepatide specifically in patients with type 2 diabetes and obesity. At 72 weeks, participants on the 15 mg dose lost 14.7% of body weight compared with 3.2% for placebo, with 82.8% of the 15 mg group achieving HbA1c <7% 18.

The 2023 American Association of Clinical Endocrinology guidelines recommend tirzepatide as first-line pharmacotherapy for patients with BMI ≥30 seeking ≥15% total body weight loss, citing superior efficacy versus other approved agents 19. The Endocrine Society's 2024 guideline on obesity pharmacotherapy echoes this positioning, recommending GIP/GLP-1 receptor agonists for patients with obesity-related complications 5.

Oregon-specific considerations: approximately 30% of Oregon adults meet obesity criteria (BMI ≥30), according to CDC data 15. Rural counties in Eastern Oregon have higher obesity prevalence (35-38%) and fewer bariatric specialists, making telehealth-prescribed GLP-1 agonists a practical intervention 15.

Comparing Zepbound Cost Options in Oregon

A direct comparison of Zepbound access pathways available to Oregon residents in 2026:

Brand Zepbound with commercial insurance + savings card: $25/month. Requires formulary coverage and PA approval. Best option for employed, commercially insured Oregonians 1.

Brand Zepbound with Oregon Medicaid: $0-$3 copay. Requires PA with BMI documentation and lifestyle modification history. Processing takes 5-14 business days 20.

LillyDirect vials (cash-pay): $399-$549/month depending on dose. No insurance needed. Available via telehealth. Uses vials rather than auto-injector pens 11.

Compounded tirzepatide (503A): $249/month average. Requires prescription from Oregon-licensed provider. Legal via state-licensed sterile compounding pharmacies 12.

Full cash-pay (retail pharmacy): $1,059/month. No PA or eligibility requirements. Available same-day at any stocked Oregon pharmacy.

Dr. Ania Jastreboff, lead investigator for SURMOUNT-1 and associate professor at Yale School of Medicine, stated in a 2023 interview: "The efficacy of tirzepatide is consistent across subgroups regardless of how patients access the medication, but sustained treatment requires sustainable cost for the individual patient" 3.

Dose Escalation and Long-Term Cost Planning

Zepbound's prescribing information specifies a mandatory dose-escalation schedule: 2.5 mg weekly for 4 weeks (initiation only, not therapeutic), then 5 mg weekly. Subsequent increases in 2.5 mg increments occur every 4 weeks to a maximum of 15 mg weekly based on tolerability and response 1.

Cost remains $1,059/month at all dose levels for brand Zepbound. This flat pricing means cost per milligram decreases as dose increases. At 15 mg weekly, cost per milligram is approximately $17.65, versus $106 per milligram at the 2.5 mg initiation dose 1.

For compounded tirzepatide, pricing typically scales with dose. Oregon patients should budget for increasing monthly costs as they titrate upward. A typical 6-month trajectory for compounded product: months 1-2 at $150/month (2.5-5 mg), months 3-4 at $249/month (7.5-10 mg), months 5-6 at $300-350/month (12.5-15 mg) 13.

Long-term treatment is expected. The SURMOUNT-4 trial demonstrated that discontinuing tirzepatide after 36 weeks of treatment resulted in regain of approximately two-thirds of lost weight by week 88, while those continuing treatment maintained their weight loss 21. Oregon patients should plan for indefinite therapy duration when calculating annual costs.

Side Effects and Monitoring Costs

Common adverse effects in SURMOUNT-1 included nausea (24-33%), diarrhea (18-25%), and constipation (15-17%), most occurring during dose escalation and resolving with continued use 3. These may require additional Oregon pharmacy purchases (ondansetron, fiber supplements) adding $10-30/month during titration.

Oregon prescribers typically order baseline and periodic monitoring labs: comprehensive metabolic panel, lipid panel, HbA1c, and thyroid function tests. Quest Diagnostics and LabCorp locations throughout Oregon process these panels at $100-200 per draw for uninsured patients; insured patients pay applicable copays 22.

The American Diabetes Association's 2024 Standards of Care recommend monitoring glycemic parameters in patients with prediabetes or diabetes initiating GLP-1/GIP agonists, with laboratory assessment every 3-6 months 22. Patients taking tirzepatide for weight management without diabetes require less intensive monitoring but should have annual metabolic panels at minimum.

Annual total cost of ownership for an Oregon patient on brand Zepbound with savings card: $300 medication + $200-400 labs + $150-300 telehealth visits = approximately $650-$1,000 per year. Without insurance: $12,708 medication + $400 labs + $300 visits = approximately $13,408 annually.